Publications
88
Citations
4,262
Est. group size
—
Recurring co-author estimate
Active years
22
Publishing since 2005
Typically publishes in teams of ~8 · 21% small-team papers (≤3 authors) · across 19 venues
- The weakest link in the orthodontic chain: Compliance, adolescence, and the burden of finishing excellence
IP Indian Journal of Orthodontics and Dentofacial Research · 2026
- Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo‐Controlled Phase 3 Trials
Arthritis & Rheumatology · 2026
- MALNUTRITION SCREENING AND REGISTERED DIETITIAN MANAGEMENT: AN INADEQUATELY ADDRESSED BURDEN AT A TERTIARY IBD CENTER
Gastroenterology · 2025
- MALNUTRITION SCREENING AND REGISTERED DIETITIAN MANAGEMENT: AN INADEQUATELY ADDRESSED BURDEN AT A TERTIARY IBD CENTER
Inflammatory Bowel Diseases · 2025
- Sa1816: INTESTINAL ULTRASOUND (IUS) INDICES DIFFERENTIALLY REFLECT DISEASE SEVERITY IN ACUTE SEVERE ULCERATIVE COLITIS (ASUC)
Gastroenterology · 2025
- Tu1972: PREOPERATIVE MALNUTRITION AND POOR PHYSICAL FUNCTION ARE ASSOCIATED WITH WORSE OUTCOMES AFTER IBD SURGERY
Gastroenterology · 2025
- Tu1965: INCREASED MUSCLE MASS AND STRENGTH IS ASSOCIATED WITH MORE FAVORABLE IBD POSTOPERATIVE OUTCOMES
Gastroenterology · 2025
- Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients with Uncontrolled Gout (UG) and Stage 3 CKD
Journal of the American Society of Nephrology · 2025
- Réduction des tophus observés chez les patients atteints de goutte non contrôlée et traités avec NASP (sirolimus nanoencapsulé et pegadricase) : résultats des études DISSOLVE de phase 3
Revue du Rhumatisme · 2025
- From optional to essential: Why the temporomandibular joint and occlusion deserve a core place in dental education curriculum
International Dental Journal of Student Research · 2025
- Efficacy and Safety of SEL-212 in Patients with Refractory Gout and CKD: A Post Hoc Analysis from the Two Phase 3 DISSOLVE Studies
Journal of the American Society of Nephrology · 2024
- The Rheumatologist as the Agent of Change: Utility of Guidelines in the Management of Gout
The Journal of Rheumatology · 2024
- POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS
Annals of the Rheumatic Diseases · 2024
- P084 Gout symptom improvements and patient outcomes with SEL-212 in gout refractory to conventional therapy: DISSOLVE I & II phase 3, double-blind, placebo-controlled clinical trials
Lara D. Veeken · 2024
- POS0033 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND OTHER SECONDARY CLINICAL OUTCOMES IN ADULTS WITH GOUT REFRACTORY TO CONVENTIONAL THERAPY TREATED WITH SEL-212: POOLED 6-MONTH DATA FROM THE PHASE 3 DISSOLVE I & II CLINICAL TRIALS
Annals of the Rheumatic Diseases · 2024
- Figshare×8
- Annals of the Rheumatic Diseases×7
- Gastroenterology×6
- Arthritis & Rheumatology×4
- Lara D. Veeken×2
- Puja Khanna
Medicine · University of Michigan
- Dhanita Khanna
Medicine · University of Michigan
- Dinesh Khanna
Medicine · University of Michigan
- Erin Kim
Medicine · University of Michigan
- Harry D. Momo
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile